ABSTRACT: Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. Methods: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross-sectional and longitudinal cohorts of ALS patients with clinical parameters. Results: We identified 7 miRNAs (miR-192-5p, miR-192-3p, miR-1, miR-133a-3p, miR133b, miR-144-5p, miR-19a-3p) that were upregulated and 6 miRNAs (miR-320c, miR-320a, let-7d-3p, miR-425-5p, miR320b, miR-139-5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR-136-3p, miR-30b-5p, miR-331-3p, miR-496) correlated positively and change in 1 miRNA (miR-2110) correlated negatively with changes in clinical parameters in longitudinal analysis. Discussion: Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression.
might be a valuable tool to predict disease onset and progression. miRNAs are short (18-25 nucleotides), noncoding RNA that regulate gene expression by inhibiting messenger RNA (mRNA) translation or affecting mRNA degradation. 14 Recent studies suggest that several diseases, including neurodegenerative disorders, are associated with the altered expression of miRNAs. 15 Consistent with this, differentially expressed miRNAs have been identified in plasma, serum, spinal cord, and cerebrospinal fluid (CSF) of patients with ALS. 16 However, small patient cohorts and the absence of longitudinal evaluation have posed major limitations to the translation of these findings to clinical settings.
The utility of miRNAs for treatment and diagnosis is an active area of research. Several miRNAbased therapeutics are currently in phase I and II clinical trials for numerous disease indications including hepatitis C infections, type 2 diabetes, nonalcoholic fatty liver disease, cutaneous T-cell lymphoma, and mesothelioema. [17] [18] [19] In addition, specific miRNAs are known to differentiate healthy versus disease states, and this has led to testing miRNAs as diagnostic biomarkers in the clinic for cardiovascular, neurological, and pulmonary disorders and various types of cancer. 19, 20 We sought to identify miRNAs differentially expressed in serum samples from participants with ALS compared to both healthy participants and those with other neurologic diseases. We also studied the association between miRNA expression and disease progression. Finally, using available longitudinal data, we investigated whether changes in miRNA expression correlated with changes in clinical measures over time.
MATERIALS AND METHODS
Participants. Patients included in the study met the El Escorial World Federation of Neurology Criteria 21 for clinically definite, probable, probable laboratory-supported, or possible ALS. Participants were enrolled as a convenience sample from the Massachusetts General Hospital multidisciplinary ALS clinic and were assessed clinically at each visit. ALS disease duration was calculated from the day of onset of the first weakness or spasticity symptoms. The 2 measurements used for evaluation at each visit were the ALS Functional Rating Scale-Revised (ALSFRS-R) and vital capacity (VC). 22, 23 Samples and clinical scores were collected longitudinally at approximately 3-6 month intervals. Among the 23 patients with ALS enrolled, 3 had fALS and 20 had sALS. Two of the patients with fALS had C9orf72 repeat expansions, and 1 tested positive for a SOD1 mutation. Seventeen patients (15 sALS and 2 fALS) were treated with riluzole. The remaining 6 patients were untreated. 26 Alzheimer disease (AD) patient samples (30 patients, 9 men and 21 women, average age 74 6 3.6 years) were obtained in collaboration with Dr. David Bennett, Rush Lab, Chicago, IL. Patients with AD recruited for the study were cognitively nonimpaired at the time of enrollment and ranged in age from 65 to 90 years. 24 A signed informed consent was received from all participants. Secondary use approval for other disease samples was obtained (IRB 2013P002181/BWH).
Samples and Analysis. Blood samples were collected in glass red top serum vacutainer tubes without additives (BD Biosciences, Franklin Lakes, NJ). Each sample was centrifuged at 2,000 RPM for 10 min to separate serum and then stored at 280 8C until RNA extraction. Serum was frozen within 2 h of the blood draw. Multiple freeze-thaw cycles were avoided by storing the samples in aliquots.
RNA was isolated by using the miRcury kit (Exiqon, Waltham, MA) and converted to complimentary DNA (cDNA) by using a synthesis kit from Exiqon (Woburn, MA). Prepared cDNAs were stored at 220 8C until use. Locked nucleic acid (LNA)-SYBR green-based real-time polymerase chain reaction (Exiqon, Waltham, MA) (PCR; ) custom made panels based on those described in a prior study 25 containing 191 miRNAs were used for profiling in the first set. Normalization was performed by using the mean expression of miRNA with the best stability index (i.e., those that were stably expressed in our sample set). NormFinder software was used to calculate the stability index. 47 We used 4 normalizing miRNAs (miR-15b-5p, miR19a-3p, miR-126-3p, miR-425-5p). The following formula was used to calculate the normalized quantitation cycle (Cq) values: normalized Cq 5 average Cq 2 assay Cq.
Statistical Analysis. The expression of circulating miRNAs was compared between HCs and patients with ALS, MS, and AD. For the patients with ALS, the following 3 comparisons were made: (1) baseline miRNA expression with baseline ALSFRS-R, baseline VC and disease duration, (2) baseline miRNA expression with change in ALSFRS-R and VC measured over time during multiple patient visits, and (3) changes in miRNA expression with changes in ALSFRS-R and VC measured over time.
For each miRNA, the number of participants who had a detectable expression level and the mean expression level were calculated for each group (ALS, HC, MS, AD). Patients with ALS were then compared with each of the 3 comparison groups separately by using a Wilcoxon rank sum test. Patients with fALS and sALS were also compared with each other by using a Wilcoxon rank sum test. Patients treated with Riluzole were compared with untreated patients using a Wilcoxon rank sum test.
A Wilcoxon rank sum test was used so that participants with miRNA levels below the limit of detection (missing or undetected values) could contribute to the analysis. Undetected expression values were assigned a value 1 less than the minimum detectable miRNA level across all participants. The summary statistics and P values were calculated for the 3 group comparisons (Supp. Info. Tables 1-3 ). In addition to the individual miRNA comparisons, 2 logistic regression models were built with ALS versus all other groups as the outcomes and combinations of miRNAs. The first logistic regression model included all miRNAs that were significantly upregulated in patients with ALS in all 3 group comparisons (ALS vs. HC, ALS vs. MS, ALS vs. AD), and the second logistic regression model included all miRNAs that were significantly downregulated in patients with ALS. Subsequent logistic regression models were generated by comparing these miRNAs expression specifically within the individual groups (ALS vs. HC, ALS vs. MS, ALS vs. AD). The miRNAs chosen for inclusion in the multivariable logistic regression model were significantly associated with ALS in univariate analyses (Supp. Info. Tables 1-3 ). The logistic regression coefficients and area under the receiver operating characteristic (ROC) curve were calculated.
To investigate the clinical utility of miRNAs in patients with ALS, we assessed both the cross-sectional and the longitudinal associations between miRNAs and clinical outcomes. To assess the cross-sectional relationship between miRNAs and clinical measures, we estimated Spearman's correlation coefficient between the baseline measurement of each miRNA and the ALSFRS-R, VC, and ALS disease duration. In addition to the cross-sectional comparison, the change in each of the clinical measures over the course of follow-up was calculated by fitting a linear regression with the ALSFRS-R or VC as the outcome and the time since the first measurement as the predictor. To assess whether baseline miRNA was predictive of change in clinical measures, we estimated Spearman's correlation coefficient between the baseline miRNA measurement and the slope in clinical measure. To assess whether change in miRNA was associated with change in clinical measures, we calculated the slope for each miRNA using a linear regression model and then estimated Spearman's correlation coefficient between the 2 slope estimates. If the miRNA and clinical measure changed in the same direction (i.e., both increased or decreased), then they were positively correlated; however, if 1 parameter decreased while the other increased, they were negatively correlated. In addition to the main analyses, we also completed the same analyses adjusting for use of riluzole; the results were largely unchanged, so only the unadjusted results are reported.
In all comparisons, P-values were also adjusted for multiple comparisons by using false discovery rate (FDR); these values are provided in Supporting Information Tables 1-3 . Statistical analysis was completed in the statistical packages R (www.r-project.org) and Stata/IC version 14 (www.stata.com). In all analyses, P < 0.05 was considered statistically significant. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis with miRNAs was carried out in DIANA miRPath. 27 
RESULTS
Comparison of miRNA Expression Among Patients with ALS, HCs, and Patients With Other Diseases. We found that 102 miRNAs were differentially expressed in at least 1 group comparison. Figure 1 shows the group comparison and the miRNAs that were specifically upregulated or downregulated in a single comparison and in comparison with 1 other group. We found 21 miRNAs that were differentially expressed only between ALS and HC, 11 miRNAs that were differentially expressed only between patients with ALS and MS, and 38 miRNAs that were differentially expressed only between patients with ALS and AD. In addition to the miRNAs that were unique to a particular group comparison, 13 miRNAs were differentially expressed specifically in patients with ALS compared with all other groups. Seven miRNAs were upregulated in patients with ALS, and 6 miRNAs were downregulated in patients with ALS compared with the 3 groups ( Table 2) . A logistic regression model was built with the 7 miRNAs that were upregulated in ALS in all comparisons. The estimated logistic regression coefficients are provided in Table 2 , and the ROC curve is displayed in Figure 2A . The area under the ROC curve for this model was 0.86, showing clear discrimination between ALS and other groups. The 6 miRNAs that were downregulated in ALS in all comparisons were used to build a single model with the estimated logistic regression coefficients provided in Table 2 ; the ROC curve is shown in Figure 2B . The area under the ROC curve for this model was 0.89. Additionally, logistic regression models were generated for specific group comparisons by using the combination of 7 miRNAs that were upregulated in ALS in all 3 comparisons and the 6 miRNAs that were downregulated in ALS compared with all other group comparisons (Fig. 2) .
Correlation of miRNAs With Clinical Measures. The estimated Spearman's correlation coefficient comparing baseline miRNA expression with baseline ALSFRS-R, VC, and disease duration is provided in Supporting Information Table 4 , and a summary of the significant miRNAs is provided in Table 3 . A positive correlation indicated that increased miRNA expression correlated with higher ALSFRS-R and VC values (Table 3) . Four miRNAs significantly correlated with ALSFRS-R score, 1 positively and 3 negatively (Table 3) . Eight miRNAs negatively correlated with VC, whereas 6 positively correlated (Table 3) . For disease duration, 7 miRNAs were negatively correlated (a decreased expression of these miRNAs is associated with longer disease duration), and 1 miRNA was positively correlated with disease duration (Table 3) . The estimated Spearman's correlation coefficients comparing baseline miRNAs and longitudinal change in ALSFRS-R and VC are provided in Supporting Information Table 5 . A positive correlation indicates that a high baseline expression is associated with a higher slope value or a lesser decrease with time, whereas a negative correlation indicates that a high baseline miRNA expression is associated with a lower slope value or a greater decrease with time. Four miRNAs correlated positively, and 2 miRNAs correlated negatively with ALSFRS-R change (Table 4) . Eight miRNAs correlated positively, and no miRNAs correlated negatively with changes in VC over time (Table 4) . Finally, we compared the change in miRNAs with the change in each clinical measure over time to assess whether miRNAs can be used as biomarkers of disease progression (Supp. Info. Table  5 ). The change in 4 miRNAs correlated positively with the change in both clinical measures, and the change in miR-2110 correlated negatively with the change in both ALSFRS-R and VC (Table 5 ).
In a subanalysis between patients with sALS and patients with fALS, we found that the expression of miR-574-3p was significantly higher in patients with sALS compared with patients with fALS, and miR-628-3p was significantly lower in patients with sALS compared with patients with fALS (Supp. Info. Table 6 ). In another subanalysis comparing Riluzole treated versus untreated patients is shown in Supplementary Info Table 7 .
DISCUSSION
ALS biomarkers have the potential to help elucidate the pathogenesis of ALS, identify relevant pathways for drug development, provide biological patient strata, and, after much validation, even act as surrogate endpoints in clinical trials. No single biomarker can fill all these roles; in fact, each of these biomarker applications might require different characteristics. But as a group, miRNAs, which are highly varied but tightly controlled, broadly relevant, and ubiquitously involved in cellular processes, could potentially serve in many of these roles. Already, several studies have identified miRNAs in CSF, serum, plasma, leukocytes, spinal cord, and skeletal muscle biopsies from patients with ALS. 16 Using easily accessible serum samples, we have identified unique miRNA signatures that can distinguish patients with ALS from healthy participants and those with AD or MS. We also identified other miRNA expression changes that correlate with disease state at baseline and over time and still others that predict rate of ALS progression as determined by changes in miRNA expression with changes in clinical measures such as ALSFRS-R score, VC, and disease duration.
We observed some overlap with previously reported miRNAs (reviewed in Cloutier et al. 16 ). For instance, miR-1, miR-133a-3p, and miR-133b were previously found to be upregulated in plasma and serum samples from patients with ALS. 28 In addition, miR-133b was also found to be downregulated in spinal cord biopsies. 29 Here we report that miR-1, miR-133a-3p, and miR-133b are upregulated in serum from patients with ALS compared with other groups, and, consistent with this, their expression negatively correlates with VC. Another interesting miRNA, miR-451, has been reported to be downregulated in blood leukocytes from patients with ALS, 30 and we found that its expression positively correlates with VC, indicating that lower expression is associated with worse disease. miR-142-3p was found to be upregulated in spinal cord tissue samples from patients with ALS. 29, 31 In our analysis, miR-142-3p negatively correlated with disease duration, and low miR-142-3p expression correlated with rapid change in VC in our longitudinal studies.
In addition to previously identified miRNAs, we also found striking physiological relevance for other novel miRNAs recognized in this study. Among the 7 upregulated miRNAs, miR-1, miR133a-3p, and miR-133b are muscle-specific miRNAs, or myomiRs, that are critical for the development and maintenance of skeletal muscles. 32, 33 Previous studies have indicated an enhanced expression of myogenic differentiation 1 and myogenin in patients with ALS, suggesting an active differentiation process in these patients. 34 Muscle atrophy is prevalent in patients with ALS, and an enhancement of homeostatic regulators of myogenesis might be a mechanism to cope with the muscular atrophy. miR-133b and miR-206 are encoded by a bicistronic transcript and have been studied in the SOD1G93A mouse model. Upregulation of these miRNAs is associated with the onset of neurological symptoms in mice as a compensatory mechanism to regenerate neuromuscular synapses. 35 Our observation of enhanced expression of myomiRs in serum samples from patients with ALS might be related to muscle atrophy and, therefore, serve as markers of disease onset and prognosis.
Among downregulated miRNAs, miR-320a is known to target aquaporins (AQP) 1 and 4. 36 The overexpression of AQP4, mostly in perivascular astrocytes, has been observed in mouse and rat models of ALS and is associated with breakdown of the blood-brain barrier (BBB). 37 Impairment of the BBB, although subtle, has been described in patients with ALS. 38 Other members of the miR-320 family, miR-320b and miR-320c, were also found to be downregulated in our samples. miR320a, miR-320b, and miR-320c are proposed diagnostic markers for schizophrenia because their expression is downregulated in the peripheral blood of patients with schizophrenia. 39 However, the molecular mechanism by which they might be contributing to schizophrenia remains to be investigated. An analysis of the common pathways regulated by miR-320a, miR-320b, miR-320c, miR-425-5p, let-7d-3p, and mir-139-5p points to their role in the Hippo signaling pathway. 27 Mammalian sterile 20-like kinase 1 (MST1) is a protein kinase implicated in the Hippo pathway, and its homozygous deletion delays the onset of ALS in mice. 40 One potential hypothesis for this effect is that MST-1 induces neuronal cell death and muscle degeneration upon phosphorylation. Although MST-1 is not a direct target of these miRNAs, they target upstream regulators such as large tumor suppressor kinase 1 and 2 (LATS1, LATS2), and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein c (YWHAG) implicated in the Hippo pathway. 27, 41 Previous studies have shown that miR-574-3p is implicated in TDP-43 binding and is downregulated in lymphoblast cell lines in all patients except those with SOD1 mutation. 12 Furthermore, both miR-628-3p and miR-574-3p are implicated in regulating DNA methyltransferases. There is growing evidence to indicate epigenetic changes in the promoter region of genes involved in processes such as calcium homeostasis, excitotoxicity, and oxidative stress in patients with sALS. 42 Comparison of sporadic versus familial ALS was not the primary focus of the current investigation. Therefore, further investigation with larger patient groups is warranted to identify epigenetic signatures that might potentially distinguish groups of patients with ALS.
Our longitudinal analysis suggests that miRNAs may be useful as prognostic biomarkers to provide information about expected rate of disease progression. We identified 5 miRNAs whose change in expression over time correlated with changes in both ALSFRS-R score and VC. Among these, the low expression of miR-136-3p, miR-30b-5p, miR-331-3p, and miR-496 and the high expression of miR-2110 correlated with more rapid disease progression. A KEGG pathway analysis of miR-136-3p, miR-30b-5p, and miR-331-3p showed that these miRNAs are involved in the extracellular matrix (ECM) receptor pathway. Gene expression profile analysis in fibroblasts from patients with fALS indicated an enrichment in ECM receptor pathway and focal adhesion pathway molecules compared with healthy controls. 43 Accordingly, an upregulation of ECM-related genes was also observed in astrocytes from SOD1G93A mice, and these genes were downregulated in the spinal cord from presymptomatic SOD1G93A mice compared with wildtype mice. Some of the genes in this pathway that are upregulated in these disease models include tumor necrosis factor (TNF), endothelin1 (END1), and angiotensin (AGT). 44, 45 In a recent study comparing 12 different commercially available miRNA expression platforms for studying differential expression in serum, the LNAbased quantitative PCR platform from Exiqon showed good reproducibility, accuracy, and the highest specificity. 46 Therefore, we believe this is a robust system to measure the expression of miRNAs. However, because of the sample size and the exploratory nature of this study there were some limitations. First, although serum samples from patients with MS and AD were used as controls to identify differentially expressing miRNAs in ALS, the use of serum samples from patients with other neurological disorders whose phenotypes overlap with that of ALS, such as inclusion body myositis and multifocal motor neuropathy, will provide better differential diagnostic information. Second, not all miRNAs were expressed in every sample. In the group comparisons, the diverse age groups of participants in the group with AD compared with others might account for this loss of miRNA expression. Finally, only a subset of miRNAs remained significant after correcting for multiple comparisons according to the FDR (Supp. Info. Tables 1-3) .
This study correlates changes in miRNA expression with changes in clinical parameters over time, providing insight into disease onset and progression. It provides the groundwork for confirmatory work in the future with a comprehensive validation in a larger cohort of patients, ideally with genomic information, collected in a multicenter study. This will enable the confirmation of these miRNAs as markers of diagnosis and disease prognosis as well as surrogate markers to serve as primary and secondary outcomes in clinical trials.
